46 results
Page 2 of 3
6-K
p0we rrc1
28 Apr 22
Current report (foreign)
4:06pm
6-K
EX-99.3
3k3l bawkr2xi
11 Apr 22
Current report (foreign)
5:14pm
6-K
EX-99.3
vf056h9in8orkd0bz
24 Mar 22
Galapagos publishes 2021 annual report and announces Biographies of proposed new board members
8:13pm
6-K
EX-99.2
3yf9jn zoywd
24 Mar 22
Galapagos publishes 2021 annual report and announces Biographies of proposed new board members
8:13pm
6-K
EX-99.11
te7oxa4cy08vqvx 64
24 Mar 22
Galapagos publishes 2021 annual report and announces Biographies of proposed new board members
8:13pm
6-K
EX-99.1
90anv19l59bbca ats
24 Feb 22
Galapagos 2021 results set stage for future growth
5:19pm
6-K
EX-99.1
s1erphl4ujj 1uqt8ebl
27 Jan 22
Galapagos appoints Paul Stoffels as Chief Executive Officer
12:00am
6-K
EX-99.1
fd2mypox t8
29 Nov 21
Galapagos completes patient recruitment for MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease
6:00am
6-K
EX-99.3
suxbq7neflr xm2di581
11 May 21
Current report (foreign)
2:10pm
6-K
EX-99.2
07a46lcitkpxo oa2u8
11 May 21
Current report (foreign)
2:10pm
6-K
EX-99.2
6mqe z0vs69m1gd0vdy
25 Oct 19
Solid third quarter 2019 performance with strong balance sheet for continued R&D growth
5:00pm
6-K
EX-99.2
95j03q xph87yfvroxh
29 Aug 19
Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration
4:44pm
6-K
EX-99.3
e59aunipibwyxrkl
29 Aug 19
Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration
4:44pm
424B5
1sy8 ii9vj
13 Sep 18
Prospectus supplement for primary offering
12:00am
424B5
jioqsu245xg0e7v4rd
18 Apr 17
Prospectus supplement for primary offering
12:00am